SCHEMBL8773581

SCHEMBL8773581

Clc1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.67
TDP1 Q9NUW8 1/20 0.67
ESR1 P03372 3/20 0.56
ESR2 Q92731 3/20 0.56
TSHR P16473 1/20 0.53
CYP1A2 P05177 1/20 0.50
LMNA P02545 2/20 0.44
CYP2A6 P11509 1/20 0.44
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ORAI1 Q96D31 1/20 0.41
ORAI2 Q96SN7 1/20 0.41
ORAI3 Q9BRQ5 1/20 0.41
TRPV6 Q9H1D0 1/20 0.41
KDM4E B2RXH2 2/20 0.39
GAA P10253 2/20 0.39
G6PD P11413 1/20 0.39
IDO1 P14902 2/20 0.37
TDO2 P48775 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2454269 1.00 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2TSHR
SCHEMBL11837589 0.97 CYP3A4 (0.63) CYP3A4TDP1ESR1ESR2TSHR
1,4-Dichlorobenzene SCHEMBL11803922 0.97 CYP3A4 (0.71) CYP3A4TDP1ESR1ESR2TSHR
Chlorobenzene SCHEMBL7171696 0.89 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2TSHR
SCHEMBL152775 0.88 LMNA (0.57) CYP3A4TDP1ESR1ESR2TSHR
SCHEMBL31325559 0.85 LMNA (0.53) CYP3A4TDP1ESR1ESR2TSHR
SCHEMBL11551608 0.85 LMNA (0.53) CYP3A4TDP1ESR1ESR2TSHR
Bromide SCHEMBL28414241 0.85 LMNA (0.53) CYP3A4TDP1ESR1ESR2TSHR
SCHEMBL16094788 0.85 TDP1 (0.92) CYP3A4TDP1ESR1ESR2TSHR
SCHEMBL1301471 0.85 TDP1 (0.92) CYP3A4TDP1ESR1ESR2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188007-A1 PRODUCTION METHOD OF 2,7-OCTADIEN-1-OL KURARAY CO., LTD. (JP) 2025-06-12 US disclosed
EP-4484401-A1 PRODUCTION METHOD OF 2,7-OCTADIEN-1-OL Kuraray Co., Ltd. (JP) 2025-01-01 EP disclosed
US-20240002313-A1 [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2024-01-04 US disclosed
CN-117098749-A [11C] Labeled acyclic retinoids, central nervous system activators and methods for their manufacture 国立研究开发法人国立长寿医疗研究中心 2023-11-21 CN disclosed
EP-4249058-A1 [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME National Center for Geriatrics and Gerontology (JP) 2023-09-27 EP disclosed
WO-2023162973-A1 PRODUCTION METHOD OF 2,7-OCTADIEN-1-OL 株式会社クラレ 2023-08-31 WO disclosed
CN-115055207-B Method for preparing aryl phosphine by reducing aryl phosphine oxide 清华大学 2023-07-21 CN disclosed
WO-2023113576-A1 COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2023-06-22 WO disclosed
EP-3586961-B1 METHOD FOR MANUFACTURING CATALYST LIQUID KURARAY CO (JP) 2023-06-07 EP disclosed
US-11628430-B2 Method for manufacturing catalyst liquid KURARAY CO., LTD. (JP) 2023-04-18 US disclosed
US-4593128-A Using a di- or triphenylphosphine compound ATLANTIC RICHFIELD COMPANY (US) 1986-06-03 US disclosed
EP-0174174-A2 A method of stabilising hydroxy-containing polymers of butadiene or substituted derivatives thereof ELF ATOCHEM S.A. (FR) 1986-03-12 EP disclosed
US-4480137-A ALDEHYDES FROM ALPHA-OLEFINS; HEAT RESISTANCE; CATALYST SELECTIVITY EXXON RESEARCH & ENGINEERING COMPANY (US) 1984-10-30 US disclosed
US-4454353-A Trihydrocarbyl silyl substituted alkyl diaryl phosphine transition metal complexes and their use as homogeneous hydroformylation-aldolization catalysts EXXON RESEARCH AND ENGINEERING CO. (US) 1984-06-12 US disclosed
US-4451673-A REACTING OLEFINS WITH CARBON MONOXIDE AND HYDROGEN TO YIELD ALDEHYDES EXXON RESEARCH AND ENGINEERING CO. (US) 1984-05-29 US disclosed
US-4450299-A ALDEHYDES FROM UNSATURATED ACYCLIC HYDROCARBONS, CARBON MONOXIDE AND HYDROGEN EXXON RESEARCH AND ENGINEERING CO. (US) 1984-05-22 US disclosed
US-4257973-A USING ORGANOPHOSPHORUS-PALLADIUM HALIDE COORDINATION CATALYST E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-03-24 US disclosed
US-3992456-A BY REACTING BUTADIENE WITH WATER IN THE PRESENCE OF A PALLADIUM CATALYST UNION CARBIDE CORPORATION (US) 1976-11-16 US disclosed
US-3987009-A TRANSITION METAL CATALYST COMPOSITIONS UNION CARBIDE CORPORATION (US) 1976-10-19 US disclosed
US-3972928-A Regulating plant growth with quaternary phosphonium aliphatic carboxamide salts BAYCHEM CORPORATION (US) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002313-A1 [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME NR2E3, FABP7, RARB CYP3A4 2009/4885TDP1 3661/4885ESR1 1588/4885
US-11628430-B2 Method for manufacturing catalyst liquid OSGEP, PNP, ALK CYP3A4 297/4885TDP1 3301/4885ESR1 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.